U.S. markets closed

Myriad Genetics, Inc. (MYGN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
18.63+0.46 (+2.53%)
At close: 04:00PM EDT
18.63 0.00 (0.00%)
After hours: 04:05PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Triple Moving Average Crossover

Triple Moving Average Crossover

Previous Close18.17
Bid18.59 x 1400
Ask21.02 x 900
Day's Range18.06 - 18.74
52 Week Range16.02 - 36.95
Avg. Volume544,251
Market Cap1.497B
Beta (5Y Monthly)1.57
PE Ratio (TTM)N/A
EPS (TTM)-0.11
Earnings DateAug 01, 2022 - Aug 05, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est22.33
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
-45% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for MYGN

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Myriad Genetics, Inc.
    MYGN: Raising target price to $19.00MYRIAD GENETICS INC has an Investment Rating of HOLD; a target price of $19.000000; an Industry Subrating of High; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
    Fair Value
    Economic Moat
    3 days agoArgus Research
View more
  • GlobeNewswire

    Myriad Genetics Issues Inaugural Environmental, Social and Governance Report

    2021 report demonstrates focus on ESG initiatives supporting health equity, social justice, and sustainability SALT LAKE CITY, June 28, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today released its first environmental, social and governance (ESG) report, highlighting increased efforts to support a healthy, equitable and sustainable society. The report outlines actions taken to expand access to genetic testing, advance socia

  • Zacks

    Here's Why You Should Retain Myriad Genetics (MYGN) Stock Now

    Myriad Genetics (MYGN) continues to benefit from strong testing volumes, but forex remains a woe.

  • GlobeNewswire

    Myriad Genetics Teams Up with Epic to Make Genetic Testing Accessible to More Patients with Electronic Health Record (EHR) Integration

    Healthcare providers can easily order Myriad’s genetic tests for the more than 250 million patients within Epic’s networkPartnership bolsters Myriad’s growth plan to scale customer-centric, tech-enabled commercial capabilities with over 600 EHR integrations this year SALT LAKE CITY, June 23, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a partnership with Epic, the industry leading healthcare software company,